SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Trillium Therapeutics Inc. (TRIL.TO) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 36/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TRIL.TO
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio13,336.13
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.70
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2011 |
$-5.11 |
$0.00 |
$-3.11M |
- |
| 2012 |
$-17.15 |
$0.00 |
$-1.07M |
- |
| 2013 |
$-2.97 |
$0.00 |
$-4.03M |
- |
| 2014 |
$-2.64 |
$0.00 |
$-11.1M |
- |
| 2015 |
$-1.60 |
$0.00 |
$-10.62M |
- |
| 2016 |
$-3.02 |
$0.00 |
$-23.61M |
- |
| 2017 |
$-3.67 |
$0.00 |
$-35.86M |
- |
| 2018 |
$-2.24 |
$0.00 |
$-31.19M |
- |
| 2019 |
$-1.65 |
$124K |
$-41.62M |
-33566.1% |
| 2020 |
$-0.70 |
$148K |
$-59.35M |
-40098.6% |
